AstraZeneca Wilson disease candidate further demonstrates copper removal from tissues
hapabapa/iStock Editorial via Getty Images         

AstraZeneca (NASDAQ:AZN) said its candidate for Wilson disease, ALXN1840, showed three times greater removal of copper from tissues compared to the standard of care.
Detailed results from the FoCus phase III trial found that those on the once-daiulyÂ  therapy achieved a response at four weeks that was sustained through 48 weeks.
Wilson disease is a rareÂ  genetic condition in which the body's toÂ  remove excess copper is negatively impacted.
In May, the U.S. FDA approved Cuvrior (trientine tetrahydrochloride) from private French biotech Orphalon, the first new treatment for Wilson disease in more than 50 yearss.